- About us
Health expenditure worldwide will continue to grow. People are living to an increasingly advanced age thanks to improved medical care, with the proportion of the ageing population thereby steadily increasing. In addition, lifestyle and old age diseases – mostly chronic diseases – are playing an increasing role, many of them also due to lifestyle changes. The sharp increase in the occurrence of sun-induced non-melanoma skin cancer, as well as the associated medical treatment and prophylaxis are consequences of this.
With PDT, the company considers itself to be excellently positioned in both Europe and the USA. As a biopharmaceutical company, Biofrontera specializes in the development and commercialization of dermatological drugs. Biofrontera has been marketing PDT and its flagship drug for the treatment of non-melanoma skin cancer and its precursors in the EU since 2013 and in the USA since 2016.
The company intends to make it available for further dermatological indications in the future.
XepiTM (active ingredient: ozenoxacin) for the treatment of impetigo is marketed by Biofrontera as another promising product in the US portfolio. The cream is one of the few topical therapy options with a novel mode of action that has received marketing approval in dermatology in recent years.
Innovation requires vision and the courage to transform ideas into groundbreaking products.
With consistency, Biofrontera has evolved into an expert and innovation driver in the development of dermatological drugs, each of which is a solution for a special medical need in the treatment of skin diseases.